Marinomed Biotech AG Expands into Compounding Services

Marinomed Biotech AG has announced its strategic expansion into pharmaceutical compounding services using its Marinosolv® technology. This move represents a new business opportunity for the company, with expectations of initial revenues by late 2026 or early 2027. Marinomed aims to leverage Marinosolv's advanced solubilization capabilities, offering pharmacies a standardized process for producing compounded products.

The expansion targets global demand for customized medicines, benefiting specific patient and physician needs. Applications range from ophthalmic preparations to rapid-onset formulations. The company plans to focus on markets with high demand for personalized treatments, particularly in German-speaking countries and regions like the UK, Nordics, and Benelux.

Marinomed emphasizes quality, compliance, and strategic partnerships, aiming to establish B2B alliances and invest in formulation R&D. This move positions Marinomed to enhance patient care with tailored medicinal solutions.